2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - R02-R05
Treatment Considerations, Combination Therapy, Drug Development, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

523 Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A open-label, multicenter, Phase Ib/II study

Youshan Zhao, PhD, Xuliang Shen, MD2, Hu Zhou, MD3, Min Zhang4, Sujun Gao, MD5, Luxi Song, MD6, Zongjiu Jiao, MD7, Zhenya Hong8, Jianping Hao9, Zhihua Zhang10, Tiejun Gong11, Junying Wu12, Hongmei Ma13, Xue Lan Zuo14, Guohua Yang15, Shanli Lao16, Ting Zhang17, Xu Li18, Ding Yu19, Xiquan Zhang20, Chunkang Chang, MD, PhD21
1 Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Heping Hospital Affliated to Changzhi Medical College, Changzhi, China
3 The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
4 Union Hospital Tongji College Huazhong University of Science and Technology, Wuhan, China
5 Bethune First Hospital of Jilin University, Changchun, China
6 Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 Xingtai People's Hospital, Xingtai, China
8 Tongji Hospital Affiliated to Tongji Medical College, Wuhan, China
9 The First Teaching Hospital of Xinjiang Medical University, Urumqi, China
10 Affiliated Hospital of Chengde Medical University, Chengde, China
11 The Institute of Hematology and Oncology, The First Hospital of Harbin, Harbin, China
12 Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
13 Cangzhou People's Hospital, Cangzhou, China
14 Zhongnan Hospital of Wuhan University, Wuhan, China
15 Wuxi People's Hospital, Wuxi, China
16 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Nan jing, China
17 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Nan jing, China
18 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Nan jing, China
19 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Nan jing, China
20 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., Nan jing, China
21 Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

PURPOSE

Myelofibrosis (MF) remains challenging to treat with Janus kinase (JAK) inhibitor monotherapy due to limited response durability and lack of disease modification. Concurrent inhibition of JAK, RHO-associated kinase (ROCK), and bromodomain and extraterminal (BET) proteins may address multiple pathogenic pathways simultaneously. This phase Ib/II study evaluated the safety and efficacy of rovadicitinib, a first-in-class JAK/ROCK inhibitor, in combination with TQB3617, a BET inhibitor, in patients with intermediate- or high-risk MF.

METHODS

In this open-label, multicenter study, JAK inhibitor–naïve and -experienced patients received rovadicitinib 10 mg twice daily continuously plus TQB3617 0.1 mg once daily on a 2-weeks-on/1-week-off schedule (21-day cycles). The recommended phase II dose was established in a 3+3 dose-escalation phase. Primary endpoint was the proportion of patients achieving ≥35% reduction in spleen volume from baseline at week 24 (SVR35) by independent central review. This trial is registered at clinicaltrials.gov, NCT06122831.

RESULTS

Fifty-two patients were enrolled, including 15 JAK inhibitor-naïve and 37 JAK inhibitor-experienced patients. At week 24, SVR35 was achieved in 93.3% (14/15; 95% CI, 68.1-99.8) of naïve patients and 48.1% (13/27; 95% CI, 28.7-68.1) of experienced patients, with corresponding median spleen volume reductions of -47.5% and -35.0%, respectively. At week 48, the corresponding SVR35 rates were 12 of 14 (85.7%; 95% CI, 57.2–98.2) and 7 of 19 (36.8%; 95% CI, 16.3-61.6), respectively. Symptom improvement (≥50% reduction in total symptom score, TSS50) was observed in 53.3% of naïve and 63.0% of experienced patients, while bone marrow fibrosis improved by ≥1 grade in 26.7% and 44.4% of patients at week 24. In addition, TSS50 were observed at week 48 in 9/14 (64.3%, 95% CI, 35.1-87.2) of naïve patients and 12/19 (63.2%; 95% CI, 38.4-83.7) of experienced patients. At baseline, 25 of 42 patients who recevied combination treatment tested positive for the JAK2 V617F mutation. By week 24, any reduction in variant allele frequency (VAF) was seen in 19 of these 25 patients (76.0%), including 4 (16.0%) with a ≥20% reduction and 1 (4.0%) with a ≥50% reduction. Notably, among patients with baseline hemoglobin <90 g/L (n=6), median hemoglobin increased from 86.5 to 110.0 g/L at week 24. The most common grade ≥3 treatment-related adverse event was thrombocytopenia (17.3%), with no bleeding events reported. Dose reductions due to adverse events occurred in 44.2% of patients, and only one patient discontinued treatment permanently. Throughout the treatment course, neither leukemic transformation nor death was observed in any patient.

CONCLUSION

Rovadicitinib plus TQB3617 demonstrated promising efficacy across spleen, symptom, and fibrosis endpoints, with favorable anemia outcomes and manageable thrombocytopenia in both JAK inhibitor–naïve and -experienced patients with myelofibrosis. These findings support further evaluation of this triple-target (JAK, ROCK, and BET) combination strategy.

Chunkang Chang, MD, PhD: No relevant conflicts of interest to declare.